Skip to main content
  • Home
  • Articles
    • Archive from 2022 July
    • Archive 1960 to 2022 June
    • Accepted Articles
    • Published Ahead-of-Print
    • Supplement
  • About
  • For Authors
  • Podcasts

Restenosis in Percutaneous Coronary Intervention - Is Drug-Eluting Stent the Answer?

< Back to Listing

Share this Article

Singapore Med J 2003; 44(9): 482-487
Restenosis in Percutaneous Coronary Intervention - Is Drug-Eluting Stent the Answer?

  • Abstract
  • PDF

VYT Lim, YL Lim
Correspondence: Dr Victor Y T Lim, victor_lim@cgh.com.sg

ABSTRACT
The long-term success of percutaneous coronary intervention in the treatment of coronary artery disease is hampered by the occurrence of restenosis, which often necessitates repeat hospitalisations or coronary interventions. The advent of drug-eluting stents, particularly those coated with sirolimus and paclitaxel, may be the breakthrough in the battle against restenosis that interventional cardiologists have been waiting for, and we review the currently available evidence for this. Despite the growing enthusiasm, we should not forget that this new technology is still in its relative infancy, and there remain many unanswered questions, particularly about the long-term effect of using these stents.

Keywords: angioplasty, drug-eluting stent, paclitaxel, restenosis, sirolimus
Singapore Med J 2003; 44(9): 482-487

http://smj.org.sg/sites/default/files/4409/4409ra1.pdf
×

Around the Site

Home

About SMJ

For Reviewers

Sign Up for Alerts

Issues

Current Issue

All Issues

Online First

Supplement

CME

For Authors

Instructions for Authors

Submit Manuscript


Follow us on:
        

More Links

Contact Us

Copyright

Advertise

SMJ Forms

Privacy Policy

SMA Home

Copyright 2021. Singapore Medical Association. All Rights Reserved.